Down 54%, Should You Buy the Dip in Rigetti Computing (RGTI) Stock?

Rigetti Computing’s shares have tumbled from a $56.34 peak in Oct 2025 to about $26 after a period of profit-taking despite announced product rollouts; revenue rose 60% in 2022 but fell 8% in 2023 and 10% in 2024 and is forecast to drop ~30% to $7.6M in 2025. Net losses widened from $72M in 2022 to $201M in 2024 with analysts projecting a $215M loss in 2025 and a narrowing to ~$80M by 2027 contingent on ambitious scaling (100+ qubits in 2026, 1,000+ by end-2027) that the company has already missed once; the peak $18.3B market cap implied extreme multiples (≈2,408x 2025 revenue, 398x 2027 revenue) and current $8.3B valuation still implies ~182x 2027 sales, while share count has risen ~160%, raising dilution and execution risk amid strong competition from IBM, Google and IonQ.

Analysis

Market structure: Big tech (IBM, GOOGL/GOOG) and alternative-architecture players (IONQ) are the net beneficiaries as they own scale, cloud distribution and government relationships; pure-play, vertically integrated firms like RGTI (RGTI) are the immediate losers because capital intensity and missed milestones compress their optionality. Competitive dynamics favor incumbents with installed bases — expect pricing power and share gains for cloud providers that bundle quantum into hybrid HPC offerings, pushing small vendors into niche or acquisition paths within 12–36 months.

Risk assessment: Tail risks include a failed 100+/150+/1,000+ qubit roadmap (operational), loss of government contracts or new export controls (regulatory), and a capital-market squeeze forcing >30% dilution or bankruptcy (financial); these are 5–25% probability but catastrophic for equity holders. Short-term (days–months) risk is elevated volatility and further equity dilution; long-term (2–5 years) the market will bifurcate into a few winners and consolidation or IP monetization for losers. Hidden dependencies: access to cryogenics supply, foundry capacity for superconducting chips, and timing of government procurement; catalysts are quarterly revenue guidance, NQI-like contract awards, and public demos of scaled qubit systems.

Trade implications: Tactical short RGTI exposure is preferred: consider initiating a 1–2% portfolio short position (or buy 90-day puts 10–25% OTM) with a hard stop at a 30% adverse move and target 70–90% downside if revenue/dilution trends continue. Pair trade: long IONQ or IBM (1–3% weight) vs short RGTI to capture architecture and scale divergence; add NVDA exposure (1–2%) for a hedge on broader AI/compute upside. Rotate away from small-cap quantum pure-plays into large-cap cloud/HPC suppliers over the next 3–12 months to reduce idiosyncratic dilution risk.

Contrarian angles: The market may be over-penalizing IP/acquisition optionality — a strategic buyer (IBM, Google, or a defense contractor) could offer a >100% takeover premium within 12–36 months if RGTI proves unique integration tech; that makes calibrated long-dated OTM call spreads or buy-write strategies a viable asymmetric play sized at <0.5% of book. Historical precedent (biotech binary outcomes) suggests option-based, asymmetric sizing rather than large directional equity exposure; beware that such outcomes are binary and time-sensitive to catalyst windows.

Key Decisions for Investors

• Initiate a tactical short position in RGTI equal to 1–2% of portfolio notional or buy 90-day puts 10–25% OTM sized to 0.5–1% of portfolio; set stop-loss at 30% adverse move and plan to cover into any positive 100+/150+ qubit demo or government contract announcement within 30–90 days.
• Establish a pair trade: long IONQ (1–3% weight) and/or IBM (1–3%) vs short RGTI (1%); thesis: trapped-ion scale and cloud incumbency will capture commercial demand over the next 12–36 months, target IRR 20–50% if RGTI guidance disappoints.
• Buy a low-cost asymmetric bet: purchase RGTI 12-month OTM call spreads (e.g., 100–200% OTM) sized to 0.25–0.5% of portfolio to capture M&A upside while limiting downside; hedge by selling short-dated (90-day) puts to fund part of the spread only if willing to accumulate equity at a stressed valuation.
• Reduce exposure to small-cap quantum pure-plays by 50% and rotate proceeds into NVDA (1–2%) and GOOG/IBM (2–4%) over 1–3 months to capture secular AI/HPC demand and de-risk dilution and execution risk inherent in RGTI-like names.
• Monitor three specific catalysts in the next 30–180 days before adding size: (1) RGTI quarterly revenue and cash-burn cadence, (2) any award/renewal from U.S. government quantum programs, and (3) public demonstrations or peer releases from IBM/Google showing commercial advantage; act only if at least two catalysts materially revise cash-flow or strategic outlook.